BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 22240917)

  • 1. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats.
    Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
    J Cardiovasc Pharmacol; 2012 May; 59(5):458-64. PubMed ID: 22240917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.
    Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
    Pharmacology; 2012; 89(1-2):44-52. PubMed ID: 22302095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
    Nariai T; Fujita K; Kawane K; Mori M; Nakayama R; Matsuda K; Katayama S; Fukuda N; Hori S; Iwata M; Hasegawa F; Suzuki K; Kato H
    J Pharmacol Exp Ther; 2015 Jul; 354(1):2-9. PubMed ID: 25922341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
    Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
    J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats.
    Michaelis M; Hofmann PJ; Götz F; Bartel C; Kienitz T; Quinkler M
    Horm Metab Res; 2012 Apr; 44(4):291-5. PubMed ID: 22266825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
    Han WQ; Wu LY; Zhou HY; Zhang J; Che ZQ; Wu YJ; Liu JJ; Zhu DL; Gao PJ
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):583-8. PubMed ID: 19673944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
    Ménard J
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):45-52. PubMed ID: 15134800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
    Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.
    Brandish PE; Chen H; Szczerba P; Hershey JC
    J Pharmacol Toxicol Methods; 2008; 57(2):155-60. PubMed ID: 18304838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
    Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
    J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats.
    Fujisawa G; Muto S; Okada K; Kusano E; Ishibashi S
    Transl Res; 2006 Sep; 148(3):149-56. PubMed ID: 16938653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
    Pérez-Rojas J; Blanco JA; Cruz C; Trujillo J; Vaidya VS; Uribe N; Bonventre JV; Gamba G; Bobadilla NA
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F131-9. PubMed ID: 16835406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of polyphenol-containing azuki bean (Vigna angularis) extract on blood pressure elevation and macrophage infiltration in the heart and kidney of spontaneously hypertensive rats.
    Sato S; Mukai Y; Yamate J; Kato J; Kurasaki M; Hatai A; Sagai M
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):43-9. PubMed ID: 18047626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats.
    Schupp N; Kolkhof P; Queisser N; Gärtner S; Schmid U; Kretschmer A; Hartmann E; Oli RG; Schäfer S; Stopper H
    FASEB J; 2011 Mar; 25(3):968-78. PubMed ID: 21135038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
    Mervaala EM; Malmberg L; Teräväinen TL; Laakso J; Vapaatalo H; Karppanen H
    Br J Pharmacol; 1998 Jan; 123(2):195-204. PubMed ID: 9489606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antihypertensive agents on blood pressure and the progress of renal failure in partially nephrectomized spontaneously hypertensive rats.
    Katsumata H; Suzuki H; Ohishi A; Nakamoto H; Saruta T; Sakaguchi H
    Lab Invest; 1990 Apr; 62(4):474-80. PubMed ID: 2185377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
    Liang YH; Wang JM; Zhou Y; Jiang XJ; Jiang H; Huang CX
    Life Sci; 2004 Aug; 75(15):1871-8. PubMed ID: 15302230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.